Natrol, Inc. company was founded in 1980 and is headquartered in Chatsworth, California. Natrol, Inc. manufactures and distributes nutritional products. The company offers nutritional and dietary supplements, functional herbal teas, and sports nutrition products for heart and digestive health, weight management and energy, mood and sleep support, eye and joint health, and children's and brain health. It also provides Natrol Immune Boost for the wellness of bodys immune system. In addition, the company manufactures supplements for third parties. It offers its products through retailers in the United States and subsidiaries in the United Kingdom and Hong Kong, as well as through distribution partners internationally.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. Medical Nutrition company's customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey.

Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Laboratorios Almirall can help patients with a lot of ailments. The pharmaceutical company develops, manufactures, and markets drugs for a wide range of conditions affecting the digestive, central nervous, respiratory, and cardiovascular systems. Products include ebastine (antihistamine), aceclofenac (anti-inflammatory), and almotriptan (anti-migraine drug). The company, which is the leading drugmaker in Spain, operates from offices in Europe and Mexico and markets its drugs in more than 70 countries. Laboratorios Almirall is currently focusing its research efforts on treating asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, and dermatological problems, among others.

Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.

Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

CEDRA is a contract research organization, deep in the heart of Texas. CEDRA conducts phase I-IV clinical drug trials at its facilities in Austin and San Antonio, including general pharmacodynamics (what a drug does to a live human body) and pharmacokinetics (what a live human body does to a drug). The company also performs bioequivalency studies for generic pharmaceutical makers. It has experience in testing drugs ranging from allergy medicines to pain management and Parkinson's drugs. Its research customers include pharmaceutical and biotechnology drug makers, as well as the federal government. CEDRA is a division of Worldwide Clinical Trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.